

## Full list of SPSN publications, 2004-2026

1. Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005.  
Skowronski DM, Gilbert M, Tweed SA, et al. *Can Commun Dis Rep* 2005;31:181-92.
2. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.  
Skowronski DM, Masaro C, Kwindt TL, et al. *Vaccine* 2007;25:2842-51.
3. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006–2007.  
Skowronski DM, De Serres G, Dickinson J, et al. *J Infect Dis* 2009;199:168–179.
4. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants.  
Janjua NZ, Skowronski DM, De Serres G, et al. *J Infect Dis* 2012;205:1858-68.
5. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada.  
Skowronski DM, De Serres G, Crowcroft NS, et al. *PLoS Med* 2010;7:e1000258.
6. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.  
Skowronski DM, Janjua NZ, De Serres G, et al. *BMJ* 2011;342:c7297.
7. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.  
Skowronski DM, Janjua NZ, De Serres G, et al. *Clin Infect Dis* 2012;55:332-42.
8. Community-acquired respiratory viruses and co-infection among patients of Ontario sentinel practices, April 2009 to February 2010.  
Peci A, Winter AL, Gubbay JB, et al. *Influenza Other Respir Viruses* 2013;7(4):559-66.
9. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.  
De Serres G, Skowronski DM, Wu XW, Ambrose CS. *Euro Surveill.* 2013;18(37). pii:20585.
10. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-Season and cross-lineage protection with unchanged vaccine.  
Skowronski DM, Janjua NZ, Sabaiduc S, et al. *J Infect Dis.* 2014;210:126-137.
11. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013.  
Skowronski DM, Janjua NZ, De Serres G, et al. *Euro Surveill.* 2013;18(5). pii: 20394.
12. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.  
Skowronski DM, Janjua NZ, De Serres G, et al. *PLoS One.* 2014;9(3):e92153.

13. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada's sentinel surveillance network, January 2014.  
Skowronski D, Chambers C, Sabaiduc S, et al. *Euro Surveill.* 2014;19(5). pii: 20690.
14. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season.  
Skowronski DM, Chambers C, Sabaiduc S, et al. *J Infect Dis.* 2015;212:726-39.
15. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's sentinel physician surveillance network, January 2015.  
Skowronski DM, Chambers C, Sabaiduc S, et al. *Euro Surveill.* 2015;20(4). pii: 21022.
16. Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality.  
Savage RD, Winter AL, Rosella LC, et al. *Euro Surveill.* 2015;20(16):21100.
17. Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses.  
Skowronski DM, Sabaiduc S, Chambers C, et al. *Euro Surveill.* 2016;21(3):30112.
18. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season.  
Skowronski DM, Chambers C, Sabaiduc S, et al. *Clin Infect Dis.* 2016;63:21-32.
19. Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.  
Chambers C, Skowronski DM, Sabaiduc S, et al. *Euro Surveill.* 2016;21(11).
20. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.  
Skowronski DM, Chambers C, Sabaiduc S, et al. *Euro Surveill.* 2017;22(6). pii: 30460.
21. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-2011 to 2014-2015.  
Skowronski DM, Chambers C, De Serres G, et al. *J Infect Dis.* 2017;215:1059-1099.
22. Beyond antigenic match: possible agent-host and immune-epidemiological influences on influenza vaccine effectiveness during the 2015-2016 season in Canada.  
Skowronski DM, Chambers C, Sabaiduc S, et al. *J Infect Dis* 2017;216:1487-1500.
23. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.  
Skowronski DM, Chambers C, De Serres G, et al. *Euro Surveill.* 2018;23(5).
24. Should sex be considered an effect modifier in the evaluation of influenza vaccine effectiveness?  
Chambers C, Skowronski DM, Rose C, et al. *Open Forum Infect Dis* 2018;5(9):ofy211.

25. Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.  
Skowronski DM, Leir S, Sabaiduc S, et al. *Euro Surveill.* 2019;24(4).
26. Vaccine effectiveness against lineage-matched and -mismatched influenza B viruses across 8 seasons in Canada, 2010-2011 to 2017-18.  
Skowronski DM, Chambers C, De Serres G, et al. *Clin Infect Dis* 2019;68:1754-57.
27. Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: possible cohort effect following the 2009 influenza pandemic.  
Skowronski DM, Leir S, De Serres G, et al. *Euro Surveill* 2019;24(15):1900104.
28. Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).  
Skowronski DM, Sabaiduc S, Leir S, et al. *Euro Surveill.* 2019;24(46).
29. Influenza vaccine does not increase the risk of coronavirus or other non-influenza respiratory viruses: retrospective analysis from Canada, 2010-11 to 2016-17.  
Skowronski DM, Zou M, Clarke Q, et al. *Clin Infect Dis.* 2020;71:2285-2288.
30. Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020.  
Skowronski DM, Zou M, Sabaiduc S, et al. *Euro Surveill.* 2020;25(7):2000103.
31. Influenza vaccine effectiveness by A(H3N2) phylogenetic sub-cluster and prior vaccination history: 2016-17 and 2017-18 epidemics in Canada. Skowronski DM, Leir S, Sabaiduc S, et al. *J Infect Dis* 2022;225:1387-98.
32. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.  
Kim S, Chuang ES, Sabaiduc S, et al. *Euro Surveill.* 2022;27(38):2200720.
33. Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.  
Skowronski DM, Chuang ES, Sabaiduc S, et al. *Euro Surveill.* 2023;28(5):2300043.
34. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).  
Skowronski DM, Zhan Y, Kaweski SE, et al. *Euro Surveill.* 2024;29(7):2400076.
35. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25.  
Separovic L, Zhan Y, Kaweski SE, et al. *Euro Surveill.* 2025;30(4):2500059.
36. Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.  
Varma A, Andrews N, Carazo S, et al. *Vaccine* 2025;62:127567

37. Effectiveness of 2024/25 KP.2 vaccine against outpatient COVID-19 in Canada.  
Separovic L, Sabaiduc S, Zhan Y, et al. *Influenza Other Respir Viruses*. 2026 Mar;20(3):e70222.
38. Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025–2026 season.  
Sabaiduc S, Kaweski S, Separovic L, et al. *JAMMI*. 2025 Oct 31;10(4):281-298.
39. Interim 2025/26 influenza vaccine effectiveness estimates with immuno-epidemiological considerations for A(H3N2) subclade K protection, Canada, January 2026.  
Separovic L, Sabaiduc S, Zhan Y, et al. *Euro Surveill*. 2026;31(5):pii=2600068.
40. Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respiratory virus co-circulation. Skowronski DM, Zhan Y, Kaweski SE, et al. *Euro Surveill*. 2026 May;31(18).